Talk:Myeloproliferative neoplasm

History

doi:10.1182/blood-2008-03-07796 - historical review. JFW | T@lk 21:54, 8 September 2008 (UTC)

"Not a Cancer"?

The blanket statement about "not being a cancer" for such a diverse group of clonal neoplasms that includes several conditions with the name "leukemia" seems at the very least confusing. There are other clonal conditions some with adverse prognoses that are probably in the same category (think MGUS proceeding variously to Waldenstroms or indolent forms of multiple myeloma ). It might be more helpful to clarify that the leukemias can be slowly progressing or rapidly progressing and that clonal diseases are part of a spectrum and may interconvert. — Preceding unsigned comment added by 2601:9:D80:47F:B5C8:E4EC:FAAB:7114 (talk) 21:41, 3 January 2014 (UTC)

So rather than getting into another edit war, perhaps we can hash out our differences here? — Preceding unsigned comment added by 2601:9:D80:47F:6081:F838:5513:A01 (talk) 21:42, 3 January 2014 (UTC)

Treatment

Though not curable, there are treatments, for example phlebotomy and hydroxyurea. Needs updating to inlcude this? Kognos (talk) 17:00, 22 December 2011 (UTC)

CALR mutations

The following was added:

“ An article in the New England Journal of Medicine in late 2013 asserted that: "Most patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK2 or MPL alteration carried a somatic mutation in CALR. The clinical course in these patients was more indolent than that in patients with the JAK2 V617F mutation." ”

The paper in question (doi:10.1056/NEJMoa1311347) is a primary source, and I am in no doubt that its findings will eventually find their way into secondary sources, particularly if they can be replicated. Until then, perhaps we shouldn't feel compelled to mention this. JFW | T@lk 23:21, 21 December 2013 (UTC)

Deleting that edit because it is based on "primary content" seems really quite bizarre. I've been following the topic for years and this appeared to be a major advance in the understanding of these disease. I have no personal stake in this issue. (No relative with any of these condtions, no consulting fees from drug companies, no stock in any startups.) Please refer us to the Wikipedia rule that primary sources should not be acceptable for support of content on a scientific topic. In fact, the advice in the guidelines is to rely on third party source including " reputable medical journals, ...". If the NEJM is not a reputable medical journal then the phrase has no meaning. — Preceding unsigned comment added by 2601:9:D80:47F:64BD:14A4:FE78:191 (talk) 06:04, 3 January 2014 (UTC)

I added both the second article (satisfying the expressed desire for "replication") and the editorial comment (satisfying the expressed desire to have independent ratification that this was an important and useful finding.)

The large studies in the paired NEJM articles show that the CALR mutations are more prevalent than the MPL mutations and deserve a more prominent mention.

Two suggestions:

After explaining the new and proper term is MPN, MPD is used throughout the article. Time to switch?

I think the proper name for this page is plural: Myeloproliferative neoplasms. It is a group of diseases. Note that every time the term was used in the article, it was used in the plural. The only time it is ever used in the singular in a sentence such as "polycythemia vera is a myeloprolierative neoplasm".

Anyone want to to act on these suggestions?

IiKkEe (talk) 20:55, 17 April 2014 (UTC)

I'm not a medical expert, so I won't make this edit myself. In the Causes sction is this statement:”Mutations in CALR have been found in the majority of JAK2 and MPL-negative essential thrombocythemia and myelofibrosis “. I believe this to be correct and in line with the latest research, but further down in the Essential Thrombocythemia and Primary Myelofibrosis sections, CALR is not mentioned at all. I think it should be mentioned there also for those who may have skipped down to a specific section without reading the Causes section, which applies to all 4 diseases. JAK2 mutations are mentioned in Causes and for each disease. Thanks! 71.17.72.133 (talk) 03:31, 14 September 2014 (UTC)Doug G71.17.72.133 (talk) 03:31, 14 September 2014 (UTC)

References

title and abbreviation

Two suggestions:

It is pointed out that the new and proper term is MPN not MPD, yet MDP used throughout the article. Time to switch?

I think the title of this article should be plural: Myeloproliferative neoplasms. Note that every time the term is used in the article, it is used in the plural. The only time it is used in the singular is like in a sentence "polycythemia vera is a myeloproliferative neoplasm" but even then it is more customary to say "polycythemia vera is one of the myeloproliferative neoplasms". Consider title change?

IiKkEe (talk) 21:05, 17 April 2014 (UTC)

Response criteria consensus

doi:10.1182/blood-2014-10-607341 JFW | T@lk 10:45, 23 March 2015 (UTC)

ohys??

Although not a malignant neoplasm like other cancers,<ilstilDIEFROMit!..81.11.206.29 (talk) 16:24, 15 October 2016 (UTC)

nope

All MPNs arise from precursors of the myeloid lineages in the bone marrow.<pmf.candoLYMFOBLASTCRISIS(stemcelthathigh!81.11.206.29 (talk) 16:54, 15 October 2016 (UTC)

Familial forms

doi:10.1111/bjh.14713 JFW | T@lk 08:28, 21 August 2017 (UTC)

Review in Blood

doi:10.1182/blood-2017-06-782037 JFW | T@lk 20:58, 9 December 2017 (UTC)